We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.
- Recent PTCT Stock Price: $43.46
- Yearly Gain for PTCT stock: 53.53%
- Market Cap for PTCT stock: $3.48B
- P/E Ratio for PTCT stock: -5.948
Will PTCT's stock price go up? Is there an accurate PTCT stock forecast available?
TipRanks.com reports that PTC Therapeutics currently has 13 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $51.62. The target pricing ranges from a high PTCT forecast of $72.00 down to a low forecast of $35.00. PTC Therapeutics (PTCT)’s last closing stock price was $43.46 which would put the average price target at 18.78% upside.
In addition, TradingView issued a Strong Sell rating for PTCT stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PTCT stock.
Other analysts covering PTCT include:
- Madhu Kumar of Goldman Sachs issued a Sell rating with the price target of $ 35 on 1 day ago
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $ 52 on 1 day ago
- Yigal Nochomovitz of Citi issued a Buy rating with the price target of $ 63 on 1 day ago
- Tazeen Ahmad of Bank of America Securities issued a Sell rating with the price target of $ 42 on 1 day ago
If you are wondering if PTCT is a good stock to buy, here are 3rd party ratings for PTCT stock:
- TipRanks.com: Hold
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 42% (105 out of 251)
What is the sentiment on the street regarding PTC Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for PTCT stock: Very Bullish
- Blogger Consensus for PTCT stock: Bullish
- Media Buzz for PTCT stock: Very Low
- Insider Signal for PTCT stock: Negative
- Investor Sentiment for PTCT stock: ―
- Hedge Fund signal for PTCT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on PTCT stock including scouring the social networks like PTCT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PTCT stock chart >>
Summary: Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.
- Recent KRYS Stock Price: $117.39
- Yearly Gain for KRYS stock: 114.26%
- Market Cap for KRYS stock: $3.06B
- P/E Ratio for KRYS stock: -22.468
Will KRYS's stock price go up? Is there an accurate KRYS stock forecast available?
TipRanks.com reports that Krystal Biotech currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $141.00. The target pricing ranges from a high KRYS forecast of $155.00 down to a low forecast of $130.00. Krystal Biotech (KRYS)’s last closing stock price was $117.39 which would put the average price target at 20.11% upside.
In addition, TradingView issued a Buy rating for KRYS stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRYS stock.
Other analysts covering KRYS include:
- Dae Gon Ha of Stifel Nicolaus issued a Buy rating with the price target of $ 145 on 2 days ago
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $ 148 on 3 days ago
- Ritu Baral of TD Cowen issued a Buy rating with the price target of $ 130 on 3 days ago
- Debjit Chattopadhyay of Guggenheim issued a Buy rating with the price target of $ 130 on 3 days ago
If you are wondering if KRYS is a good stock to buy, here are 3rd party ratings for KRYS stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 44% (111 out of 251)
What is the sentiment on the street regarding Krystal Biotech? (Current ratings compiled by TipRanks.com)
- News Sentiment for KRYS stock: Very Bullish
- Blogger Consensus for KRYS stock: Bullish
- Media Buzz for KRYS stock: Very High
- Insider Signal for KRYS stock: Negative
- Investor Sentiment for KRYS stock: Very Positive
- Hedge Fund signal for KRYS stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on KRYS stock including scouring the social networks like KRYS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KRYS stock chart >>
Summary: Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.
- Recent MRTX Stock Price: $38.40
- Yearly Gain for MRTX stock: -24.44%
- Market Cap for MRTX stock: $2.55B
- P/E Ratio for MRTX stock: -3.384
Will MRTX's stock price go up? Is there an accurate MRTX stock forecast available?
TipRanks.com reports that Mirati Therapeutics currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $61.33. The target pricing ranges from a high MRTX forecast of $82.00 down to a low forecast of $40.00. Mirati Therapeutics (MRTX)’s last closing stock price was $38.40 which would put the average price target at 59.71% upside.
In addition, TradingView issued a Strong Sell rating for MRTX stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MRTX stock.
Other analysts covering MRTX include:
- Gena Wang of Barclays issued a Buy rating with the price target of $ 75 on 22 hours ago
- Eric Joseph of J.P. Morgan issued a Hold rating with the price target of $ 53 on 22 hours ago
- Evan Seigerman of BMO Capital issued a Hold rating with the price target of $ 40 on 22 hours ago
- Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 50 on 22 hours ago
If you are wondering if MRTX is a good stock to buy, here are 3rd party ratings for MRTX stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 44% (111 out of 251)
What is the sentiment on the street regarding Mirati Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRTX stock: Very Bullish
- Blogger Consensus for MRTX stock: Bullish
- Media Buzz for MRTX stock: Medium
- Insider Signal for MRTX stock: Negative
- Investor Sentiment for MRTX stock: Very Negative
- Hedge Fund signal for MRTX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on MRTX stock including scouring the social networks like MRTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRTX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
